Relay Therapeutics exec sells shares to cover taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. executive Donald A. Bergstrom, President of R&D, reported the sale of 2,237 shares of common stock on July 28, 2026 at $18.61 per share. The sale covered income tax withholding on the vesting of 5,012 RSUs on July 27, 2026. After the transaction, he directly held 407,660 shares, including 10,025 shares underlying RSUs.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 2,237 | $18.61 | $42K |
Footnotes (2)
- F1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,012 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
- F2. Includes 10,025 shares underlying RSUs.
Key Figures
Key Terms
restricted stock units financial
income tax withholding obligations financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Relay Therapeutics (RLAY) report for Donald A. Bergstrom?
What RSU activity was disclosed in the Relay Therapeutics (RLAY) Form 4?
Was the Relay Therapeutics (RLAY) insider sale part of a discretionary trading decision?
AI-generated analysis. How Rhea-AI works. Not financial advice.